Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Angiogenesis
Published in: Angiogenesis 2/2004

01-06-2004

Tumor-derived prostaglandin E2 and transforming growth factor-β stimulate endothelial cell motility through inhibition of protein phosphatase-2A and involvement of PTEN and phosphatidy linositide 3-kinase

Author: M. Rita I. Young

Published in: Angiogenesis | Issue 2/2004

Login to get access
Metadata
Title
Tumor-derived prostaglandin E2 and transforming growth factor-β stimulate endothelial cell motility through inhibition of protein phosphatase-2A and involvement of PTEN and phosphatidy linositide 3-kinase
Author
M. Rita I. Young
Publication date
01-06-2004
Publisher
Kluwer Academic Publishers
Published in
Angiogenesis / Issue 2/2004
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-004-1027-2

Other articles of this Issue 2/2004

Angiogenesis 2/2004 Go to the issue

OriginalPaper

Withaferin A is a potent inhibitor of angiogenesis

OriginalPaper

Protamine enhances uptake of cationic liposomes in angiogenic microvessels of solid tumours

OriginalPaper

Inhibition of FGF receptor activity in glioma implanted into the mouse brain using the tetracyclin-regulated expression system

OriginalPaper

Bioinformatic analysis of primary endothelial cell gene array data illustrated by the analysis of transcriptome changes in endothelial cells exposed to VEGF-A and PlGF

OriginalPaper

Vascular Targeting Agents: Therapeutics and Diagnostic Development

OriginalPaper

Small molecule inhibitors of methionine aminopeptidase type 2 (MetAP-2) fail to inhibit endothelial cell proliferation or formation of microvessels from rat aortic rings in vitro
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits